TheEdgeResearch
Home / Stocks / IUGNF

Imugene Limited (IUGNF)

OTC Healthcare Biotechnology
$0.03 ▲ +6.90%
Market Cap
$17.0M
Sector
Healthcare
Industry
Biotechnology
Beta
2.15
52-Wk Range
0.01-0.295
CEO
Leslie Chong
Country
AU
Currency
USD

Imugene Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.03, up 6.90% on the session, giving a market capitalisation of $17.0M. On trailing twelve-month figures it carries a trailing P/E of -0.10, a net margin of 0.0%. Its beta of 2.15 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.10
Price / Sales
0.00
Price / Book
1.24
EV / EBITDA
-0.30
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.70
Current ratio
0.70
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
14
IPO date
2019-07-05
Headquarters
Sydney, NSW, AU
About Imugene Limited

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.

Comparable companies

Imugene Limited is most often compared with the following Healthcare names:

BSEMCLTEFHSCHFKNTPFMSCLFNICXFPOLBFPRNAFSPHRYVSBC
More research on IUGNF
IUGNF technical analysis IUGNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →